{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T13:20:13Z","timestamp":1649078413289},"reference-count":0,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Technology Analysis & Strategic Management"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1080\/09537320903438039","type":"journal-article","created":{"date-parts":[[2009,12,18]],"date-time":"2009-12-18T11:16:03Z","timestamp":1261134963000},"page":"19-41","source":"Crossref","is-referenced-by-count":4,"title":["Pharmaceutical patent expropriation and technology strategy: strategic options to compulsory licensing"],"prefix":"10.1080","volume":"22","author":[{"given":"Thomas A.","family":"Hemphill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","container-title":["Technology Analysis & Strategic Management"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09537320903438039","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,12,18]],"date-time":"2016-12-18T03:27:18Z","timestamp":1482031638000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.tandfonline.com\/doi\/abs\/10.1080\/09537320903438039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":0,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["10.1080\/09537320903438039"],"URL":"https:\/\/doi.org\/10.1080\/09537320903438039","relation":{},"ISSN":["0953-7325","1465-3990"],"issn-type":[{"value":"0953-7325","type":"print"},{"value":"1465-3990","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1]]}}}